Latham & Watkins represented Arcutis in the transaction.Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing novel innovations in immuno-dermatology, has announced that it…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Laura Testa
…
This content is for Standard 1 Year members only. LoginJoin Now